Skip to content
AlternativeMed

Epitalon (Epithalon)

Epitalon (epithalon) is a synthetic four-amino-acid peptide promoted for aging and sleep. See what lab, animal and small human studies show, and what FDA said in 2026.

Content last updated . This page has not been medically reviewed.

Quick answer
Epitalon, also spelled epithalon, is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) that is promoted online for longevity and sleep. No regulator we read has approved it as a medicine. The human evidence is a few small studies, mostly from one Russian research group [1], and a 2026 narrative review concluded it is "biologically active but clinically unproven". [2] FDA's own 2026 review found no clinical data supporting its safety or effectiveness for insomnia. [1]

Naming: epitalon, epithalon, epithalamin

Epitalon and epithalon are the same name spelled two ways, and AEDG is its amino-acid shorthand. Epithalamin is a different thing: a polypeptide extract originally made from the pineal gland of cattle. Epitalon was made synthetically based on the amino-acid content of that extract. FDA treats the two as different substances. [1] FDA also notes that epitalon is a common name rather than an official nonproprietary name, that free base and acetate salt forms are different ingredients, and that many sources do not say which form was used. [1] So a study of epithalamin, or of one form, cannot simply be applied to another product. See research peptide naming and identity problems.

What the research shows

  • Cells. A 2025 study reported that epitalon lengthened telomeres, the protective ends of chromosomes, in several human cell lines, including breast-cancer cell lines, partly through a cancer-associated pathway called ALT. [3] A correction notice was later published for this paper. [4] Label: preclinical (cells/animals only). Longer telomeres in a dish are not a human health outcome.
  • Animals. FDA's reviewers describe older studies in mice and monkeys, with melatonin changes in monkeys and fewer spontaneous tumors in female mice. They judged these too limited in dose, duration and sex to show whether epitalon could cause or prevent cancer. [1]
  • People. Evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa; no adequately powered randomized trial has established benefit. [2] One placebo-controlled study of a sublingual spray in 40 adults with low melatonin-metabolite levels reported higher levels after treatment, but FDA noted it did not specify blinding, and was short and small. [1] A retinal study reported a positive effect in 90% of patients, but its abstract gives no sample size or blinding details. [5] Label: promising but limited for melatonin-related biomarkers; insufficient evidence for aging, sleep disorders or any disease outcome.
  • Registered trials. ClinicalTrials.gov lists one early-phase study (48 participants, estimated) of a topical serum that includes epitalon among several peptides, not a study of epitalon alone. [6]

Marketing claims versus evidence

Claims that epitalon reverses aging, lengthens life or "resets" telomeres in people are marketing claims. Proper evidence not found for any of them in human trials of survival or disease. See peptides and aging claims.

Frequently asked questions

Are epitalon and epithalon different?

No, they are two spellings of the same name. Epithalamin is a different pineal-gland extract. [1]

Does epitalon lengthen telomeres in people?

Proper evidence not found in people. The telomere findings come from cell lines. [3]

Is epitalon approved for sleep or aging?

We found no approval from any regulator we could read. FDA's reviewers found no evidence of effectiveness for insomnia. [1]

Is it safe?

Unknown. FDA found no clinical safety data and flagged unresolved cancer and immunogenicity questions. [1]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

How to read the evidence labels

Labels used on this page: preclinical (cells/animals only), insufficient evidence, promising but limited, marketing claim and Proper evidence not found. A biomarker is a lab value, not a health outcome.

Regulatory status
  • United States. Epitalon is not a component of an FDA-approved drug, and has no USP or NF monograph. In May 2026 FDA reviewers proposed not adding it to the 503A bulks list (the list of substances pharmacies may compound from) because it is not well characterized, lacks safety data and effectiveness evidence for insomnia, and approved insomnia drugs exist. [1] The Pharmacy Compounding Advisory Committee scheduled epitalon for discussion on July 24, 2026. [7] Advisory committees give non-binding advice, and I could not read an official FDA vote record or final decision, so none is stated here. FDA's older category 2 page lists epitalon among withdrawn nominations, citing immunogenicity risk and no safety data for the proposed route. [8]
  • Other countries. FDA's briefing says no epitalon product is approved in Canada, Australia, the United Kingdom, Ireland, France, Germany, Spain, Italy and several other countries, and none is authorized by the EMA. [1] We did not read those regulators' own pages.

Laws change and this is not legal advice.

Safety
FDA's search of its adverse-event database through December 2025 found no epitalon reports, which is not evidence of safety because compounded products are rarely reported. [1] FDA flagged a theoretical cancer concern, since telomerase activation is linked to cancer, and found no two-year carcinogenicity studies. [1] It also flagged injection-related immunogenicity. See peptide safety and adverse events. For sleep problems, start with insomnia and a clinician.
References
  1. U.S. Food and Drug Administration. FDA Briefing Document for Epitalon-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (FDA review memo dated 5/12/2026). Read 2026-10-22.
  2. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026. Read 2026-10-22.
  3. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025. Read 2026-10-22.
  4. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025 (published erratum). Read 2026-10-22.
  5. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002. Read 2026-10-22.
  6. U.S. National Library of Medicine. ClinicalTrials.gov record NCT07888595, topical peptide serum study that includes epitalon. Read 2026-10-22.
  7. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (meeting page and agenda; no vote record or final decision was read). Read 2026-10-22.
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.